Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clear cell papillary RCC distinguished by unique staining pattern

Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Key clinical point: Clear cell papillary renal cell carcinoma (ccpRCC) is a recently recognized subtype of renal cell carcinoma with a unique staining pattern that can be used to distinguish this cancer. Further, vitamin D receptor-positive expression suggests that ccpRCC originates from the precursor epithelium of the distal nephron.

Major finding: Histopathologically, all 26 cases of ccpRCC exhibited a tubular and papillary architecture, covered by tumor cells with clear cytoplasm. Immunohistochemistry showed intermediate (5/26, 19%) to diffuse (21/26, 81%) and moderate (2/26, 8%) to strong (24/26, 92%) membranous staining for vitamin D receptor. All cases (26/26, 100%) were diffuse with strong cytoplasmic and fibrillar staining for cytokeratin 7 (CK7), but negative for α-methylacyl-CoA-racemase (AMACR). Each case showed diffuse (26/26, 100%) and moderate (4/26, 15%) to strong (22/26, 85%) membranous staining for carbonic anhydrase IX (CA IX). In addition, the majority of cases were negative for cluster of differentiation 10 (CD10) (20/26, 77%) and renal cell carcinoma maker (RCC-Ma) (24/26, 92%).

Study details: The clinicopathological and immunohistochemical features of ccpRCC were examined in 26 patients, mean age 53 years (range 36–74 years), with a mean tumor size of 2.5 cm (range 0.5 to 6.5 cm).

Disclosures: The authors had no relevant financial disclosures.

Source: Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Citation:

Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

This Week's Must Reads

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Must Reads in Renal Cell Carcinoma

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4